Home / Dexamethasone / United States
US ATC A01AC02 · updated 2 Nov 2026
Dexamethasone shortage in United States
Is there a Dexamethasone shortage in United States?
Yes. As of 2 Nov 2026, 17 Dexamethasone products are reported short in United States, the first since 8 Feb 2019. No return date has been given. Main reason: not stated.
Not reported short in any other country we track. All countries.
Affected products in United States
| Country | Product | Company | Since | Expected back | Reason |
|---|---|---|---|---|---|
| US | Dexamethasone Sodium Phosphate Preservative Free, Injection, 10 mg/1 mL (NDC 63323-506-01) | Fresenius Kabi USA, LLC | 8 Feb 2019 | not given | Not stated |
| US | Dexamethasone Sodium Phosphate Preservative Free, Injection, 10 mg/1 mL (NDC 70069-021-25) | Somerset Therapeutics, LLC | 8 Feb 2019 | not given | Not stated |
| US | Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 0641-0367-25) | Hikma Pharmaceuticals USA, Inc. | 8 Feb 2019 | not given | Not stated |
| US | Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 55150-304-25) | Eugia US LLC | 8 Feb 2019 | not given | Not stated |
| US | Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 63323-516-10) | Fresenius Kabi USA, LLC | 8 Feb 2019 | not given | Not stated |
| US | Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 67457-420-10) | Mylan Institutional, a Viatris Company | 8 Feb 2019 | not given | Not stated |
| US | Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 70069-025-10) | Somerset Therapeutics, LLC | 8 Feb 2019 | not given | Not stated |
| US | Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 76045-212-10) | Fresenius Kabi USA, LLC | 8 Feb 2019 | not given | Increased demand Demand increase for the drug |
| US | Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 0641-6145-25) | Hikma Pharmaceuticals USA, Inc. | 8 Feb 2019 | not given | Increased demand Demand increase for the drug |
| US | Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 0641-6146-25) | Hikma Pharmaceuticals USA, Inc. | 8 Feb 2019 | not given | Not stated |
| US | Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-01) | Fresenius Kabi USA, LLC | 8 Feb 2019 | not given | Increased demand Demand increase for the drug |
| US | Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-05) | Fresenius Kabi USA, LLC | 8 Feb 2019 | not given | Not stated |
| US | Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-30) | Fresenius Kabi USA, LLC | 8 Feb 2019 | not given | Not stated |
| US | Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-421-30) | Mylan Institutional, a Viatris Company | 8 Feb 2019 | not given | Not stated |
| US | Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-422-54) | Mylan Institutional, a Viatris Company | 8 Feb 2019 | not given | Not stated |
| US | Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-423-12) | Mylan Institutional, a Viatris Company | 8 Feb 2019 | not given | Not stated |
| US | Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 76045-210-10) | Fresenius Kabi USA, LLC | 8 Feb 2019 | not given | Not stated |
Source
U.S. Food and Drug Administration (FDA), Drug Shortages via openFDA. Official list. Shortages the FDA lists as current, plus products to be discontinued; one row per package (NDC).